Pharmacogenetics of paraoxonase activity: elucidating the role of high-density lipoprotein in disease.
about
Inflammation, infection, cancer and all that…the role of paraoxonasesPLTP activity inversely correlates with CAAD: effects of PON1 enzyme activity and genetic variants on PLTP activityEffects of dietary components on high-density lipoprotein measures in a cohort of 1,566 participants.HDL-3 is a superior predictor of carotid artery disease in a case-control cohort of 1725 participants.Lipoprotein concentration, particle number, size and cholesterol efflux capacity are associated with mitochondrial oxidative stress and function in an HIV positive cohort.Arylesterase activity is associated with antioxidant intake and paraoxonase-1 (PON1) gene methylation in metabolic syndrome patients following an energy restricted dietConcentration of Smaller High-Density Lipoprotein Particle (HDL-P) Is Inversely Correlated With Carotid Intima Media Thickening After Confounder Adjustment: The Multi Ethnic Study of Atherosclerosis (MESA)Interaction between polyphenols intake and PON1 gene variants on markers of cardiovascular disease: a nutrigenetic observational study.Dietary fatty acid intake is associated with paraoxonase 1 activity in a cohort-based analysis of 1,548 subjectsProteomic signatures of serum albumin-bound proteins from stroke patients with and without endovascular closure of PFO are significantly different and suggest a novel mechanism for cholesterol effluxLowered PON1 activities are strongly associated with depression and bipolar disorder, recurrence of (hypo)mania and depression, increased disability and lowered quality of life.Higher Levels of Oxidized Low Density Lipoproteins in Alzheimer's Disease Patients: Roles for Platelet Activating Factor Acetyl Hydrolase and Paraoxonase-1.Genotype and phenotype of salt-stimulated paraoxonase 1 (PON1) is associated with atherogenic indices in type 2 diabetesHuman paraoxonase 1 as a pharmacologic agent: limitations and perspectives
P2860
Q26849832-5B158A8F-0B78-436F-8DCF-BB64AB19CB50Q30655573-DCBD54F3-D25C-476B-823D-8BB6DE2DA17BQ34253260-84C414AF-7707-4383-8779-6A997B45A582Q35021827-C52F925D-94E5-4DD0-AE01-2756BAA7FB32Q35209036-4D25836F-05F3-4BBA-83A7-5758EC36F193Q35729080-B330F4FB-3CED-44E9-9AED-32AB4B73634FQ36956691-2B4E9985-7D61-4926-93B1-CABF9BF07EA8Q37031558-F66EDE5F-626A-40FD-B2EA-2975567C4CB3Q37427245-EE218AE4-6989-48A5-B912-D507067D15F9Q41440445-F974936D-79DA-49F4-9B41-39FC06A086B5Q47906817-FDF58F1A-71D4-415D-AA4D-21048F0C9F5EQ50595857-57B5EE8D-D8D9-4508-9275-08A5F28D3FD3Q57147406-B6EFBBD9-73CA-4985-93B1-09C817C53302Q59101037-3D9D75BF-CEE4-44B8-909C-DB346E56A348
P2860
Pharmacogenetics of paraoxonase activity: elucidating the role of high-density lipoprotein in disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pharmacogenetics of paraoxonas ...... ensity lipoprotein in disease.
@en
Pharmacogenetics of paraoxonas ...... ensity lipoprotein in disease.
@nl
type
label
Pharmacogenetics of paraoxonas ...... ensity lipoprotein in disease.
@en
Pharmacogenetics of paraoxonas ...... ensity lipoprotein in disease.
@nl
prefLabel
Pharmacogenetics of paraoxonas ...... ensity lipoprotein in disease.
@en
Pharmacogenetics of paraoxonas ...... ensity lipoprotein in disease.
@nl
P2093
P2860
P356
P1433
P1476
Pharmacogenetics of paraoxonas ...... ensity lipoprotein in disease.
@en
P2093
Clement E Furlong
Daniel Seung Kim
Judit Marsillach
P2860
P304
P356
10.2217/PGS.13.147
P577
2013-09-01T00:00:00Z